Galectin-3 is a β-galactoside-binding lectin that plays a role in the regulation of several conditions that are associated with atherosclerosis. The goal of this cross-sectional study was to assess the association of plasma galectin-3 concentrations with sonographic measures of carotid atherosclerosis in the Atherosclerosis Risk in Communities study. Linear regression was used to determine the difference and 95% confidence intervals (CIs) for carotid intima–media thickness (cIMT) by categorical and continuous representations of galectin-3. Logistic regression was used to determine the odds ratio and 95% CI, separately, for dichotomized cIMT (75th percentile = 0.9 mm) and carotid plaque and/or shadowing. Compared to those in the first quintile of galectin-3, those in the fifth quintile of galectin-3 level had higher cIMT (mean difference: 0.020 mm after multivariable adjustment; P trend = .04). Moreover, compared to those in the lowest galectin-3 quintile, those in the highest galectin-3 quintile had higher odds of carotid plaque/and or shadowing (odds ratio 1.13 after multivariable adjustment; P trend = .014). Higher levels of galectin-3 are associated with greater carotid atherosclerosis. Our findings provide support for the role of inflammatory biomarkers in the pathogenesis of atherosclerosis and suggest galectin-3 as a possible target for intervention in the prevention or management of atherosclerotic disease.
RoquerJOisA. Atherosclerotic burden and mortality. In: PreedyVRWatsonRR, eds. Handbook of Disease Burdens and Quality of Life Measures. New York, NY: Springer New York; 2010:899–918.
2.
BarqueraSPedroza-TobiasAMedinaC. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46(5):328–38.
3.
FalkE. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(suppl 8):C7–C12.
4.
HanssonGKHermanssonA. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–12.
5.
RossR. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–26.
6.
Di LellaSSundbladVCerlianiJP. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry. 2011;50(37):7842–57.
7.
RuvoloPP. Galectin 3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 2016;1863(3):427–37.
8.
FashanuOENorbyFLAguilarD. Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2017;192:19–25.
9.
LisowskaAKnappMTycińskaA. Predictive value of galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: a mid-term prospective cohort study. Atherosclerosis. 2016;246:309–17.
10.
ShimuraTShibataMGondaK. Association between circulating galectin-3 levels and the immunological, inflammatory and nutritional parameters in patients with colorectal cancer. Biomed Rep. 2016;5(5):203–7.
11.
MacKinnonACLiuXHadokePWMillerMRNewbyDESethiT. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology. 2013;23(6):654–63.
12.
ChenWSCaoZLefflerHNilssonUJPanjwaniN. Galectin-3 inhibition by a small-molecule inhibitor reduces both pathological corneal neovascularization and fibrosis. Invest Ophthalmol Vis Sci. 2017;58(1):9–20.
13.
LuYZhangMZhaoP. Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice. Mol Med Rep. 2017;16(1):647–53.
14.
NachtigalMGhaffarAMayerEP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol. 2008;172(1):247–55.
15.
NambiVChamblessLFolsomAR. Carotid intima–media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010;55(15):1600–7.
16.
BotsMLEvansGWTegelerCHMeijerR. Carotid intima–media thickness measurements: relations with atherosclerosis, risk of cardiovascular disease and application in randomized controlled trials. Chin Med J (Engl). 2016;129(2):215–26.
17.
The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129(4):687–702.
18.
SharrettARPatschWSorliePDHeissGBondMGDavisCE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1994;14(7):1098–104.
19.
FolsomARLutseyPLAstorBCCushmanM. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102(4):615–9.
20.
MatsushitaKSelvinEBashLDAstorBCCoreshJ. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55(4):648–59.
21.
LiRCaiJTegelerCSorliePMetcalfPAHeissG. Reproducibility of extracranial carotid atherosclerotic lesions assessed by B-mode ultrasound: the Atherosclerosis Risk in Communities Study. Ultrasound Med Biol. 1996;22(7):791–9.
22.
LiRDuncanBBMetcalfPA. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994;25(12):2377–83.
23.
The ARIC Study Group. High-resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. J Neuroimaging. 1991;1(4):168–72.
24.
National Institute of Heart, Lung, and Blood. Atherosclerosis Risk in Communities (ARIC) Study. Operations Manual, No. 7: Blood Collection and Processing: Version 1.0. Chapel Hill, NC: ARIC Coordinating Center, School of Public Health, University of North Carolina; 1987.
25.
HuntKJSharrettARChamblessLEFolsomAREvansGWHeissG. Acoustic shadowing on B-mode ultrasound of the carotid artery predicts CHD. Ultrasound Med Biol. 2001;(3)27:357–65.
ChamblessLEZhongMMArnettDFolsomARRileyWAHeissG. Variability in B-mode ultrasound measurements in the Atherosclerosis Risk in Communities (ARIC) study. Ultrasound Med Biol. 1996;22(5):545–54.
28.
DuncanBBMetcalfPCrouseJR3rd. for the Atherosclerosis Risk in Communities Study Investigators. Risk factors differ for carotid artery plaque with and without acoustic shadowing. J Neuroimaging. 1997;7(1):28–34.
29.
NaqviTZLeeMS. carotid intima–media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014;7(10):1025–38.
30.
BotsMLHoesAWKoudstaalPJHofmanAGrobbeeDE. Common carotid intima–media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation.1997;96(5):1432–7.
31.
LiviakisLPogueBParamsothyPBourneAGillEA. Carotid intima–media thickness for the practicing lipidologist. J Clin Lipidol. 2010;4(1):24–35.
32.
OzturkDCelikOSatilmisS. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron Artery Dis. 2015;26(5):396–401.
33.
FalconeCLucibelloSMazzucchelliI. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2011;24(4):905–13.
34.
AksanGGedikliÖKeskinK. Is galectin-3 a biomarker, a player – or both – in the presence of coronary atherosclerosis?J Investig Med. 2016;64(3):764–70.
35.
Madrigal-MatuteJLindholtJSFernandez-GarciaCE. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014;3(4):e000785.
36.
HeXWLiWLLiC. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. Sci Rep. 2017;7:40994.
37.
NachtigalMAl-AssaadZMayerEPKimKMonsignyM. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol. 1998;152(5):1199–208.
38.
KadoglouNPSfyroerasGSSpathisA. Galectin-3, carotid plaque vulnerability, and potential effects of statin therapy. Eur J Vasc Endovasc Surg. 2015;49(1):4–9.
39.
IacobiniCMeniniSRicciC. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vascular Biol. 2009;29(6):831–6.
40.
Diaz-AlvarezLOrtegaE. The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens. Mediators Inflamm. 2017;2017:9247574.
41.
DumicJDabelicSFlögelM. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616–35.
42.
WanLLiuFT. Galectin-3 and inflammation. Glycobiol Insights. 2016;6:1–9.
43.
CullenPRauterbergJLorkowskiS. The pathogenesis of atherosclerosis. In: von EckardsteinA, editor. Atherosclerosis: Diet and Drugs. Berlin, Heidelberg: Springer Berlin Heidelberg; 2005:3–70.
44.
SubhashVVLingSSMHoB. Extracellular galectin-3 counteracts adhesion and exhibits chemoattraction in Helicobacter pylori-infected gastric cancer cells. Microbiology. 2016;162(8):1360–6.
45.
SanoHHsuDKYuL. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol. 2000;165(4):2156–64.
46.
ChristensonRHDuhSHWuAH. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem. 2010;43:683–90.
47.
FinnAVKolodgieFDVirmaniR. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. 2010;30(2):177–81.
48.
SpenceJD. Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol. 2002;89(4A):10B–15B; discussion 15B-16B.
49.
QuBQuT. Causes of changes in carotid intima–media thickness: a literature review. Cardiovasc Ultrasound. 2015;13:46.
50.
MathiesenEBJohnsenSHWilsgaardTBønaaKHLøchenMLNjølstadI. Carotid plaque area and intima–media thickness in prediction of first-ever ischemic stroke. A 10-year follow-up of 6584 men and women: the Tromsø Study. Stroke. 2011;42(4):972–8.
51.
KasliwalRRBansalMDesaiDSharmaM. Carotid intima–media thickness: current evidence, practices, and Indian experience. Indian J Endocrinol Metab. 2014;18(1):13–22.
52.
PasterkampGSchoneveldAHHillenBBangaJDHaudenschildCCBorstC. Is plaque formation in the common carotid artery representative for plaque formation and luminal stenosis in other atherosclerotic peripheral arteries? A post mortem study. Atherosclerosis. 1998;137(1):205–10.
53.
AdamsMRNakagomiAKeechA. Carotid intima–media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation. 1995;92(8):2127–34.
54.
López-MelgarBFernández-FrieraLSánchez-GonzálezJ. Accurate quantification of atherosclerotic plaque volume by 3D vascular ultrasound using the volumetric linear array method. Atherosclerosis. 2016;248:230–7.
55.
SillesenHMuntendamPAdourianA. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging. 2012;5(7):681–9.
56.
RidkerPMEverettBMThurenT. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
